AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04879654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
Study NCT05228171 — intervention group
Intervention type: BEHAVIORAL
Intervention: mCC app
Description: Interviewer use of the mCC app during the 24-hour dietary recall interview.
Study NCT06082492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F FDG PET/CT
Description: Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
Study NCT06082492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT scan
Description: CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
Study NCT06082492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
Study NCT06236672 — intervention group
Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: GLP-1 RA initiated between January 2019 and December 2022
Study NCT06236672 — intervention group
Intervention type: DRUG
Intervention: basal insulin
Description: basal insulin initiated between January 2019 and December 2022
Study NCT05495620 — intervention group
Intervention type: DRUG
Intervention: Carfilzomib
Description: Intravenous~carfilzomib, lenalidomide, dexamethasone
Study NCT05495620 — intervention group
Intervention type: DRUG
Intervention: Lenalidomide
Description: Oral
Study NCT05495620 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: Oral or intravenous
Study NCT05367219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air sterilizer
Description: The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
Study NCT05399641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Each day dosing will consist of two 150mg tablets taken BID.
Study NCT04857749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
Study NCT04857749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigation Nursing
Description: With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
Study NCT05987228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thymus vulgaris
Description: 500 mg of Thymus vulgaris (capsules) was given orally twice daily
Study NCT05987228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Thymus vulgaris
Description: 500 mg of Thymus vulgaris (capsules) was given orally twice daily
Study NCT06414083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diathermy
Description: Diathermy will be used to ablate the randomized sample.
Study NCT06414083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Laser
Description: CO2 Laser will be used to ablate the randomized sample.
Study NCT06414083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Beam Coagulator
Description: Argon Beam Coagulator will be used to ablate the randomized sample.
Study NCT05075889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
Study NCT06495957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group
Description: Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes.
Study NCT06495957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Micro-acupuncture group
Description: After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes. Electrical stimulation is applied briefly for the first 30 seconds.
Study NCT04934267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise for subjects with JHS
Description: There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
Study NCT04934267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise for Controls
Description: There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
Study NCT05853354 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
Study NCT05853354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
Study NCT06199414 — intervention group
Intervention type: DEVICE
Intervention: Venous Closure
Description: Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures
Study NCT04747262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPACE
Description: SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes \& Scahill, 2014)
Study NCT05726149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real UHCDS a-tDCS
Description: Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
Study NCT05566821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRENGTH Outreach Intervention
Description: The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
Study NCT03734952 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiotherapy Program:
Description: Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
Study NCT05726149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
Study NCT05726149 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
Study NCT05726149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
Study NCT05726149 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham UHCDS a-tDCS
Description: Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
Study NCT04804124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regularized Sleep Schedule
Description: Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
Study NCT05209477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: lung ultrasound assessment
Description: In patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio \< 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~1. baseline, in supine position under protective ventilation~2. after two minute of recruitment maneuver in pressure controlled ventilation~3. at 1 hour following prone positioning application
Study NCT04787653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Otoband
Description: Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
Study NCT04787653 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
Study NCT04874636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally
Study NCT04874636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 150mg
Description: Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 300mg
Description: Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with the same volume of C1K 300mg
Description: Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 600mg
Description: Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with the same volume of C1K 600mg
Description: Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 900mg
Description: Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with the same volume of C1K 900mg
Description: Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 1200mg
Description: Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15
Study NCT05701644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with the same volume of C1K 1200mg
Description: Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
Study NCT04547530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: as above
Study NCT04547530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as above
Study NCT05979363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for elotuzumab
Description: The placebo for elotuzumab is 0.9% sterile normal saline for injection.
Study NCT05979363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRD-based regimen
Description: Bortezomib, Lenalidomide and Dexamethasone
Study NCT05243186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill workstation
Description: walking on a treadmill workstation next to desk with computer and screen
Study NCT05243186 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill workstation
Description: walking on a treadmill workstation next to desk with computer and screen
Study NCT05243186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Using prescription drug
Study NCT05243186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Using prescription drug
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diphenhydramine
Description: Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen
Description: Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: famotidine
Description: Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
Study NCT04918147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).
Study NCT04601415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG from handheld device
Description: Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
Study NCT06154616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Product
Description: Lactose-free skimmed milk
Study NCT06154616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Product: 250
Description: Lactose-free skimmed milk enriched with 250 mg aswaghanda
Study NCT06154616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Product: 250 + TRP
Description: Lactose-free skimmed milk enriched with 250 mg aswaghanda and tryptophan
Study NCT06154616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Product: 600
Description: Lactose-free skimmed milk enriched with 600 mg aswaghanda
Study NCT06239766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Risk Assessment
Description: Gail and IBIS Tools will be utilized to calculate mean lifetime breast cancer risk
Study NCT05717946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.
Description: We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
Study NCT05717946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
Study NCT05083078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.
Study NCT05083078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab will be administered subcutaneously.
Study NCT03734952 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Neoadjuvant Radiotherapy Program:
Description: Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
Study NCT03734952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy Program
Description: Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
Study NCT03734952 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant chemotherapy Program
Description: Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.